Hantavirus vaccine development progresses but faces years-long timeline despite renewed interest from cruise ship outbreak

Scientists at EnsiliTech and other institutions are advancing hantavirus vaccine candidates, primarily targeting hantaan virus using mRNA technology similar to COVID-19 platforms. A key innovation is "ensilication," which encases mRNA in a silica cage for room-temperature stability, addressing cold-chain constraints that hindered COVID vaccine distribution. The lead candidate has completed rodent trials and is estimated to require 3–4 years before human testing begins, with 5+ additional years for Phase 2/3 completion under standard development timelines. The recent Andes virus outbreak aboard the MV Hondius has reignited focus on hantavirus vaccines, and developers have not ruled out creating an ANDV-specific formulation. Historically, vaccine development has been underfunded because outbreaks are sporadic and concentrated in economically disadvantaged regions with limited pharmaceutical investment incentives. Existing vaccines in China and South Korea show mixed results and lack international availability.